These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2565 related items for PubMed ID: 17905106

  • 1. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M.
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [Abstract] [Full Text] [Related]

  • 3. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 5. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 6. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ, Karam JA, Benaim EA.
    Urology; 2004 Apr 15; 63(4):732-6. PubMed ID: 15072890
    [Abstract] [Full Text] [Related]

  • 8. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV.
    Cancer; 2006 Aug 01; 107(3):514-20. PubMed ID: 16795068
    [Abstract] [Full Text] [Related]

  • 9. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Aug 01; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 10. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 01; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 11. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M, Cavalli V, Bravi F.
    BJU Int; 2010 Mar 01; 105(5):648-51. PubMed ID: 19747358
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 13. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 14. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 15. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 16. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED, Southwest Oncology Group.
    J Urol; 2007 Nov 01; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [Abstract] [Full Text] [Related]

  • 17. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH.
    J Clin Oncol; 2006 Sep 01; 24(25):4190-5. PubMed ID: 16943536
    [Abstract] [Full Text] [Related]

  • 18. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 19. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS, Mydin A, Jones SO, Christie J, Lim JT, Truong PT, Ludgate CM.
    Int J Radiat Oncol Biol Phys; 2011 Dec 01; 81(5):e713-9. PubMed ID: 21277102
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 01; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 129.